Trial · NCT07293910
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
NCT07293910, Phase 2, Recruiting, Tanta University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection. Trials, record NCT07293910. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07293910
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
- NCT number
- NCT07293910
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 132 participants, estimated
- Lead sponsor
- Tanta University
- Conditions
- HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection, Helicobacter Pylori Infected Patients
- Interventions
- Vonoparazan, Vitamin D, Probiotic, Amoxicillin, Clarithromycin 500 mg, Proton Pump Inhibitor (PPI) Therapy
- First posted
- 2025-12-19
- Last updated
- 2026-09-09
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Detection of H pylori eradication difference among the three intervention groups through stool antigen test 4 weeks after completion of therapy. | 4 weeks after completion of therapy | We will asses the presence or absence of H pylori through fecal antigen test four weeks after completion of therapy among the three intervention groups It will be assessed as either positive or negative |
| Secondary | Changes in serum levels of the measured biological markers | 4 weeks after completion of therapy | The secondary outcome is the changes in serum levels of TNF-alpha, C-reactive protein and Malondialdehyde 4 weeks after completion of therapy |
| Secondary | Change in Gastrointestinal Symptom Rating Scale Questionnaire total score from baseline to completion of therapy and 4 weeks after completion of therapy | From baseline to completion of therapy and 4 weeks after completion of therapy | change in Gastrointestinal Symptom Rating Scale Questionnaire total score from baseline to completion of therapy and 4 weeks after completion of therapy as it is a validated, 15-item questionnaire used to assess GI symptom severity, grouping symptoms into five clusters: Reflux, Abdominal Pain, Indigestion, Diarrhea, and Constipation, scored on a 1-7 Likert scale (1=no discomfort, 7=very severe). |
| Secondary | Assessment CRP levels in both H-pylori positive and negative patients | CRP will be measured at the baseline of the study in both H-pylori positive (n=66) and negative patients (n=66) | Comparing the difference in CRP level in H-pylori positive and negative patients |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07293910
GET https://conductscience.org/api/trials/v1/NCT07293910/registered